Compare AbCellera Biologics Inc (ABCL) vs FTAI Aviation Ltd (FTAI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs FTAI Aviation Ltd — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while FTAI Aviation Ltd trades at $213.6 (market cap $23.33B). The key difference: FTAI Aviation Ltd is far larger — about 9.9× AbCellera Biologics Inc's market cap, and FTAI Aviation Ltd pays a 0.66% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | FTAI | |
|---|---|---|
Market Cap | $2.35B | $23.33B |
Sector | Health | Industrials |
52-Week High | $8.12 | $310.04 |
52-Week Low | $2.78 | $109.76 |
Enterprise Value | $1.99B | $26.37B |
Dividend Yield | — | 0.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
FTAI Aviation trades at $241.54, down 2.63% amid a bearish technical signal, though it remains supported by strong profitability with a 34.99% gross margin and 226.91% ROE. Recent earnings have missed expectations, but revenue growth is projected to rise from $2.51B in 2025 to $2.8B in 2026. Positive news includes a strategic collaboration for Boeing 737-800 freighters and a $0.45 dividend announcement.
The outlook is mixed: robust analyst consensus (100% buy ratings) and innovation in data center power solutions offer upside, but high valuations (P/E 48.11) and consecutive earnings misses pose risks. Investors should weigh growth potential against execution challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →
